• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?
RESEARCH UPDATE

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

September 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Section editor, Glen Spielmans, PhD

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

Subject:
Psychosis

Short Description:

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

Background:

What’s the optimal treatment for a first episode of psychosis? Few would argue against antipsychotic treatment, but what happens when the patient achieves remission? Is it best to continue medication indefinitely, or can the antipsychotic be reduced or discontinued altogether?

One hundred and twenty eight patients who had a first episode of psychosis (FEP) in 2001–2002 were successfully treated with antipsychotics. Of these, half were randomized to continue medications (MT), and the other half to reduce their doses (DR) after six months of remission, tapering off of medications if possible. Most (N=103) were identified seven years later for a follow-up evaluation. Of these, half (N=52) had been randomized to the symptom-guided dose reduction (DR) strategy.

At the seven-year mark, investigators evaluated the patients for both symptomatic and functional recovery. Symptoms were measured by the Positive and Negative Syndrome Scale (PANSS); function was measured by the Groningen Social Disability Scale (GSDS). Rates of symptomatic remission were essentially identical between the two groups (MT, 66.7%; DR, 69.2%) while functional remission was significantly higher in those randomly assigned to the dose-reduction group (MT, 19.6%; DR, 46.2%). “Recovery,” defined as both symptomatic and functional remission, was also higher in the DR group (MT, 17.6%; DR 40.2%).

Some patients in the MT group had discontinued antipsychotics or reduced their doses to amounts comparable to those in the DR group. When the investigators looked at all the patients who had either discontinued or reduced their doses to subtherapeutic levels (N=34), symptomatic remission was found in 85.3% (vs. 59.4% of those who had not, N=69) and functional remission in 55.9% (vs. 21.7%). These patients were also more likely to have recovered (52.9% vs. 17.4%).

When investigators looked at relapse rates over the seven-year trial, they found, perhaps not surprisingly, higher relapse rates in the DR group over the first three years. But they observed roughly equivalent rates thereafter. They argue that the key difference between the two groups after seven years is neither in relapse rate nor in level of symptoms, but in the degree of functional recovery, and that this measure requires further investigation, as it represents a better measure of patients’ overall status (Wunderlink L et al, JAMA Psychiatry 2013, online ahead of print).

TCPR’s TAKE: Few would argue that first-episode psychosis requires treatment, but this study suggests that maintenance of antipsychotics after remission may not be necessary. After the decrease or discontinuation of medications, symptoms do not become worse. In fact, function may actually improve over a seven-year period. The reasons are unclear, but they argue for a greater focus on functional improvement and psychosocial interventions than on maintenance antipsychotic medication.

General Psychiatry
KEYWORDS antipsychotics research_updates
Ccpr octnovdec2020 qa1 headshot spielmans 150x150
Glen Spielmans, PhD

CBT Moderately Effective in Improving Quality of Life for Anxiety Disorders

More from this author
www.thecarlatreport.com
Issue Date: September 1, 2013
SUBSCRIBE NOW
Table Of Contents
Antipsychotics and Anticonvulsants for Anxiety Disorders
Table - FDA Approved Medications for Anxiety
Anxiety Disorders in DSM-5 and Beyond
Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?
Fetzima Approved for Depression
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • KellieElvis2.jpeg
    General Psychiatry

    Elvis Presley and Pharmacokinetics - Part 2

    This common pharmacokinetic reaction will help you manage many bad medication reactions in psychiatric practice. But did it lead to Elvis Presley’s death? 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.